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Objective
To report the safety and efficacy results of patients enrolled
in the Italian Nivolumab Renal Cell Cancer Expanded Access
Programme.
Patients and Methods
Patients with metastatic renal cell cancer (mRCC) previously
treated with agents targeting the vascular endothelial growth
factor pathway were eligible to receive nivolumab 3 mg/kg
once every 2 weeks. Patients included in the analysis had
received ≥1 dose of nivolumab and were monitored for
adverse events (AEs) using Common Terminology Criteria
for Adverse Events (CTCAE) v.4.0.
Results
A total of 389 patients were enrolled between July 2015 and
April 2016, of whom 18% were aged ≥75 years, 6.7% had
non-clear cell RCC, 49.6% had bone and 8.2% brain
metastases, and 79% had received ≥2 previous lines of
therapy. The most common any-grade treatment-related AEs
were fatigue (13%) and rash (9%). Twenty-two patients
(5.7%) discontinued treatment because of AEs. There were no
treatment-related deaths. The objective response rate was
23.1%. At a median follow-up of 12 months, the median
progression-free survival was 4.5 months (95% confidence
interval 3.7–6.2) and the 12-month overall survival rate was
63%. Similar survival rates were reported among patients with
non-clear-cell histology, elderly patients, those with bone and/
or brain metastases, and those who had received prior first-
line sunitinib or pazopanib, or prior everolimus.
Conclusion
The safety and efficacy observed were consistent with those
reported in the pivotal Checkmate 025 trial. Results in
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patients with non-clear-cell mRCC who were elderly,
pretreated with everolimus, and had bone and/or brain
metastases encourage the use of nivolumab in these categories
of patients.
Keywords
renal cell cancer, nivolumab, expanded access programme,
real-world experience
Introduction
Nivolumab is a fully human programmed death (PD)-1)
immune checkpoint inhibitor antibody, which blocks the
interaction between PD-1 expressed on T cells and its ligands
PD-L1 and PD-L2, expressed on antigen-presenting cells and
cancer cells [1]. Nivolumab therapy induces disruption of
PD-1–PD-L1 signalling, restoring the ability of T cells to
selectively recognize and kill cancer cells [2].
In a randomized phase III trial (CheckMate 025) in patients
with metastatic RCC (mRCC), nivolumab administered after
previous vascular endothelial growth factor (VEGF)-targeted
therapy improved the median overall survival (OS) by
5.4 months and had a more favourable safety profile compared
with everolimus [3]. This difference was both statistically
significant as well as clinically relevant. In November 2015, the
US Food and Drug Administration, and in February 2016 the
European Medicines Agency, approved nivolumab for patients
with mRCC who have received prior anti-angiogenic therapy
[4,5]. A major concern, however, is whether patients enrolled
in clinical trials are representative of the overall mRCC patient
population. A large number of patients with mRCC do not
meet criteria for enrolment in phase III registrative trials, such
as those with poor performance status and those with brain
metastases, who represent nearly 10% and 15% of patients with
mRCC, respectively, after one or more lines of treatment [6,7].
Additionally, mRCC trials exclude cases with non-clear-cell
histologies which represent 15–20% of cases [8,9]; thus, little is
known about the activity of new agents in these categories of
patient.
The Italian Nivolumab Renal Cell Cancer Expanded Access
Programme (EAP) was initiated in July 2015, based on the
key clinical data described above, while nivolumab was
evaluated by the European Medicines Agency and
negotiations with the Italian Ministry of Health were ongoing,
to address the unmet medical need for patients whose disease
progressed after receiving VEGF-targeted therapy.
In the present study, we report the results of patients enrolled
in the Italian EAP and seek to evaluate the safety and efficacy
of nivolumab in mRCC in a real-world setting.
Patients and Methods
Study Population
Between July 2015 and April 2016 nivolumab was provided
by Bristol-Myers Squibb through the EAP to 95 hospitals in
Italy. A total of 490 requests were authorized, but 389
patients (80%) ultimately received at least one dose of
nivolumab, while most of the remaining 20% of patients
experienced further disease progression with clinical
deterioration prior to treatment.
Eligible patients were aged ≥18 years and had mRCC that
had relapsed after at least one prior anti-angiogenic therapy
regimen (including, but not limited to, sunitinib, sorafenib,
pazopanib, axitinib, tivozanib and bevacizumab). Prior
mammalian target of rapamycin (mTOR) inhibitors and
cytokine therapy (e.g. interleukin-2, interferon), vaccine
therapy, or treatment with cytotoxic agents were also
permitted. There was no limitation on the number of prior
treatment regimens allowed. Patients were divided into three
risk categories: favourable, intermediate and poor, according
to the International Metastatic Renal Cell Carcinoma
Database Consortium (IMDC) [10]. Inclusion criteria
permitted the presence of asymptomatic brain metastases
allowing systemic treatment with corticosteroids equivalent to
up to 10 mg daily prednisone. Mildly impaired renal function
was allowed, including serum creatinine ≤1.5 9 the upper
limit of normal or creatinine clearance ≥40 mL/min. Patients
with active autoimmune disease were excluded. Patients with
non-clear-cell histologies were also included in the present
study through an amendment during the last 3 months of
accrual. The study protocol was reviewed and approved by
ethics committees. Patients signed and dated a written
informed consent form provided by Bristol-Myers Squibb. All
data presented were prospectively collected on electronic
patient files.
Treatment
Nivolumab 3 mg/kg was administered intravenously every
2 weeks until withdrawal of consent, unacceptable toxicity or
disease progression, at the discretion of the physician.
Safety assessments included physical evaluation and
laboratory examination the day before every nivolumab
administration. Blood tests included haematology, renal and
hepatic function, pancreatic enzymes and hormone levels
(thyroid function, adrenocorticotropic hormone, cortisol).
Data on treatment-related adverse events (AEs), and
especially immuno-related AEs, as reported by each treating
physician were obtained from patient clinical files and
laboratory reports, and classified according to the Common
Terminology Criteria for Adverse Events v4.0. Treatment
beyond Response Evaluation Criteria in Solid Tumors
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(RECIST) v1.1-defined progression was allowed in patients
deriving investigator-assessed clinical benefit in the absence of
rapid disease progression and tolerating the immunological
treatment. A radiographic CT assessment was performed
every 3 months and within 6 weeks of original progressive
disease to confirm whether there was a decrease or stability in
the tumour size or continued progressive disease.
Statistical Analysis
Data were summarized as frequencies for categorical variables
and median and range values for continuous variables.
Continuous variables were compared using the Wilcoxon test.
Associations between categorical variables were assessed using
Fisher’s exact test, when appropriate. Differences were
considered statistically significant when P < 0.05. Progression-
free survival (PFS) was calculated from the start of nivolumab
treatment until disease progression or death. Alive patients
without progression were censored at the time of last follow-up.
OS was calculated from the start of nivolumab treatment until
death. Patients lost to follow-up were censored at the time of
last contact. The Kaplan–Meier method was used to estimate
PFS and OS. The log-rank test and Cox proportional hazards
regression were used to test for differences between groups.
After univariate analysis, a multivariate analysis was carried out
using a Cox regression model. All statistical analyses were
performed by an experienced biostatistician with SPSS Statistical
Software, version 21.0 (IBM_SPSS, Armonk, NY, USA).
Results
Patients
This analysis included all 389 patients who were enrolled in
the EAP at 95 centres in Italy and were treated with ≥1 dose
of nivolumab, with a median (range) follow-up of 11.9 (1–
24.7) months. Baseline patient characteristics are shown in
Table 1. Patients received a median (range) of 13 (1–49)
doses of nivolumab. At the time of the analysis 110 patients
(28.3%) were continuing treatment; among the 279 patients
(71.7%) who discontinued treatment, the reasons for
discontinuation were progressive disease in 213 patients
(76.3%), death in 21 (7.5%) and serious AEs in 22 (7.9%).
Safety
Treatment-related AEs are shown in Table 2. Treatment-
related grade 3–4 AEs occurred in 27 patients (7%). Of the 22
serious AEs that induced treatment discontinuation, 11 (50%)
were considered potentially immuno-related AEs including:
grade 4 hyperglycaemia with grade 3 diarrhoea (n = 1); grade
3 pneumonitis (n = 1); grade 3 bronchiolitis obliterans
organizing pneumonia, grade 3 asthenia (n = 1,) grade 3
hypertension (n = 1); grade 3 skin toxicity (n = 1); grade 3
tremor (n = 1); grade 2 eyelid ptosis (n = 2); grade 2 liver
toxicity (n = 1); and grade 2 hypothyroidism (n = 1). AEs
were generally manageable with treatment as per protocol-
specific guidelines. No treatment-related deaths were reported.
Tumour Assessment
Response evaluations were available for 355 (91.3%) of 389
included patients, whereas the remaining 34 cases were not
assessable as a result of early death (n = 22), early
discontinuation attributable to toxicity after a median of 3
cycles (n = 5), loss to follow-up (n = 4), and unspecified
reasons (n = 3). The best overall response in the overall
patient population was complete response in three patients
(0.8%), partial response in 87 (22.4%), stable disease in 124
(31.9%) and progressive disease in 141 (36.2%); thus, the
objective response rate (ORR) was 23.1% (90/389) in the
overall population and 25.4% (90/355) in patients who had
≥1 response assessment reported. Response rates among
patients were irrespective of age, histology, previous lines of
Table 1 Patient characteristics (N = 389).
Characteristics
Men, n (%) 291 (74.8)
Median (range) age, years 65 (34–85)
Age ≥75 years, n (%) 70 (18.0)
ECOG performance status, n (%)
0 176 (47.1)
1 174 (46.5)
2 24 (6.4)
NA 15
IMDC prognostic group, n (%)
Favourable 62 (20.2)
Intermediate 212 (69.1)
Poor 33 (10.7)
NA 82
Nephrectomy, n (%) 369 (94.9)
Histology, n (%)
Clear-cell 356 (91.5)
Non-clear-cell 26 (6.7)
Undifferentiated/Unknown 7 (1.8)
Metastasis site, n (%)
Lung 286 (73.5)
Lymph node 238 (69.2)
Bone 193 (49.6)
Liver 128 (32.9)
Brain 32 (8.2)
Number of prior systemic therapies, n (%)
1 80 (20.7)
2 137 (35.4)
≥3 170 (43.9)
First-line therapy, n (%)
Sunitinib 261 (67.4)
Pazopanib 80 (20.7)
Other 46 (11.9)
Prior everolimus, n (%)
Yes 163 (42.1)
Not 224 (57.9)
ECOG, Eastern Cooperative Oncology Group; IMDC, International Metastatic Renal
Cell Carcinoma Database Consortium; NA, not available.
100
© 2018 The Authors
BJU International © 2018 BJU International
De Giorgi et al.
therapy, brain and bone metastasis (Table 3). A total of 107
patients (27.5%) were treated beyond progression. Among
these latter patients, a subsequent response or stabilization
was achieved in 40 patients (37.4%), including partial
response in 10 (9.3%) and stable disease in 30 (28%), whereas
progressive disease was reported in 62 patients (57.9%), and
response was not assessable in five patients (4.7%). The 12-
month OS rate of these 107 patients was 77.4% (95% CI
69.0–85.8).
Survival
The 6-, 12- and 18-month OS rates were 80.0% (95% CI
75.9–84.1), 63.1% (95% CI 58.2–68.0), and 53.8% (95% CI
48.3–59.3), respectively (Fig. 1A). At the time of the analysis,
the median OS was not yet reached. The median PFS was
4.4 months (95% CI 3.7–6.2; Fig. 1B). The median time on
therapy was 7.2 months (95% CI 6.1–8.3).
In univariate analysis, age, performance status, IMDC
prognostic group and number of prior therapies were found
to be significantly associated with OS (Table 4). Prior first-
line treatment with sunitinib or pazopanib did not show any
correlation with OS after nivolumab treatment either in the
global series (Figure S1A) or in cases with second-line
nivolumab treatment (Figure S1B), whereas prior everolimus
showed a borderline association with OS (Table 4).
In multivariate analysis, age, IMDC score and number of
previous lines of treatment all remained predictors of OS
(P = 0.04, P < 0.0001 and P = 0.02, respectively; Table 4).
Discussion
The treatment of patients with mRCC has undergone great
progress in the last 10 years with the arrival of a number of
active agents, including, more recently, the immune
checkpoint inhibitor nivolumab [3,11,12]. These drugs
provide new opportunities, but the implication for general
practice is largely undocumented [11]. Moreover, patient
populations in phase II or III trials may differ from those
experienced by physicians in clinical practice [13]. This
analysis evaluated the safety and efficacy of nivolumab in
patients with mRCC treated in the EAP in Italy.
In this real-life analysis, nivolumab showed satisfactory safety
and tolerability, with only 7.9% of patients discontinuing
treatment because of serious AEs. We focused on treatment-
related toxicities and found lower incidences of grade 3–4
AEs (7%) than reported in the CheckMate 025 trial (19%;
Table 2) [3]. This may be partially explained by a slight
underreporting of side effects as patients were treated or even
admitted in local hospitals, and these events may not be
regularly registered; however, the broad mRCC population in
the Italian EAP included 49.6% of patients with bone and/or
8.2% with brain metastases, 79.3% treated from the third-line
Table 2 Rates of adverse events reported in the CheckMate 025 trial and in the Italian Expanded Access Programme.
CheckMate 025 [3] Italian EAP
Everolimus
N = 397
Nivolumab
N = 406
Nivolumab
N = 389
Any grade Grade ≥3 Any grade Grade ≥3 Any grade Grade ≥3
Treatment-related AEs, % 88 37 79 19 32 7
Fatigue 34 3 33 2 13 2
Pyrexia NR NR NR NR 3 0
Nausea 17 1 14 <1 0 0
Pruritus 10 0 14 0 0 0
Diarrhoea 21 1 12 1 5 1
Decreased appetite 21 1 12 <1 1 <1
Rash 20 1 10 <1 9 <1
Hypothyroidism NR NR NR NR 2 0
Hyperthyroidism NR NR NR NR 2 0
Hypophysitis NR NR NR NR <1 <1
Hypertransaminases NR NR NR NR 1 0
Cough 19 0 9 0 0 0
Anaemia 24 8 8 2 2 <1
Dyspnoea 13 <1 7 1 3 1
Oedema peripheral 14 <1 4 0 0 0
Pneumonitis 15 3 4 1 2 <1
Mucosal inflammation 19 3 3 0 0 0
Dysgeusia 13 0 3 0 0 0
Hyperglycaemia 12 3 2 1 0 0
Stomatitis 29 4 2 0 0 0
Hypertriglyceridaemia 16 4 1 0 0 0
Epistaxis 10 0 1 0 0 0
AE, adverse event; EAP, Nivolumab RCC Expanded Access Programme; NR, not reported.
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setting and 10.7% poor-risk patients (Table 1). These are all
subgroups that might be predicted to tolerate therapy less
well than patients in the selected population in the phase III
trial, which included only 19% of bone metastases and 16%
of patients deemed poor risk. In the registration study,
patients with brain metastases and those treated in a fourth-
line setting were not included [3]. Despite this less-defined
patient population with poorer prognosis, in the EAP analysis
efficacy results of nivolumab for the treatment of mRCC were
similar to those of the CheckMate 025 trial [3]. In particular,
the ORRs in the EAP and in Checkmate 025 were 23.1% and
25%, respectively; the median PFS was 4.4 and 4.6 months,
respectively; median OS was not reached in the EAP;
however, the 12-month OS was 63%, which approached the
76% observed in the nivolumab arm of the CheckMate 025
trial. Subgroup analyses showed that the ORR did not differ
among the following groups: elderly patients; those with non-
clear-cell histologies; different numbers of prior treatment
lines; or patients with bone and/or brain metastases (Table 3).
In particular, the cohort of 32 patients with brain metastases
was not associated with differences compared with the overall
population in terms of ORR (Table 3), and no association
with OS was observed after univariate analysis (Table 4); this
effect could be explained by cerebral activity of nivolumab as
suggested by other authors [14]. Data from the IMDC in
patients with mRCC treated with second-line VEGF-targeted
therapy showed that patients with non-clear-cell mRCC had a
worse ORR than their counterparts with clear-cell RCC (8%
vs 12%, respectively) [15]. The 26 cases with mRCC with
non-clear-cell histology in our series showed a slightly
inferior response rate of 19.2% vs 23.1% of the overall
population, suggesting that nivolumab is an active agent for
these tumours, even if longer follow-up is needed to obtain
mature data on OS. Other authors have recently reported an
Table 3 Best response in subpopulations of patients.
Population/best response n (%)
Overall population (N = 389)
Complete response 3 (0.8)
Partial response 87 (22.4)
Stable disease 124 (31.9)
Progressive disease 141 (36.2)
Could not be determined 34 (8.7)
Age ≥75 years (n = 70)
Complete response 1 (1.6)
Partial response 19 (30.2)
Stable disease 24 (38.1)
Progressive disease 19 (30.2)
Could not be determined 7 (8.8)
Non-clear-cell histology (N = 26)
Complete response 0
Partial response 5 (19.2)
Stable disease 3 (11.5)
Progressive disease 14 (53.8)
Could not be determined 4 (15.4)
Brain metastasis (n = 32)
Complete response 1 (3.1)
Partial response 5 (15.6)
Stable disease 11 (34.4)
Progressive disease 13 (40.6)
Could not be determined 2 (6.2)
Bone metastasis (n = 193)
Complete response 1 (0.5)
Partial response 37 (19.2)
Stable disease 57 (29.5)
Progressive disease 86 (44.6)
Could not be determined 12 (6.2)
Patients treated ≥third line (N = 307)
Complete response 2 (0.7)
Partial response 60 (19.5)
Stable disease 98 (31.9)
Progressive disease 120 (39.1)
Could not be determined 27 (8.8)
Patients at risk
time, months
time, months
Patients at risk
389 295 193 85 2
389 154 92 33 1
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Fig. 1 Kaplan–Meier estimate of (A) overall survival and (B) progression-
free survival in all patients.
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objective response in seven (20%) of 35 patients with non-
clear-cell mRCC treated with nivolumab, but even in that
study follow-up was too short to have data on OS [16].
Larger series including different histological subtypes with
longer follow-up are needed to better characterize the
biological activity of nivolumab in these subsets of tumours.
In a post hoc analysis of the Checkmate 025 study, the impact
of baseline characteristics, including prognostic score and
prior therapy, on the clinical outcome has been recently
evaluated [17]. The median OS was longer in both arms in
patients with better IMDC prognostic scores and with prior
sunitinib or pazopanib therapy. Moreover, a trend towards
better OS for patients treated with nivolumab with prior
pazopanib vs sunitinib was observed in the Kaplan–Meier
analyses [17]; however, an interaction test revealed a
significant interaction for risk group only but no evidence for
other subgroups. In line with these results, in the Italian EAP,
IMDC score was the strongest factor able to predict OS,
whereas no impact of prior sunitinib or pazopanib was shown
(Table 4 and Figure S1A,B).
In the preliminary exploratory analysis of the French Nivoren
study of 528 consecutive patients with mRCC treated with
nivolumab as a second or further line of treatment, the
authors showed a borderline but statistically significant
prognostic impact of previous everolimus (hazard ratio [HR]
1.39, CI 1.01–1.92; P = 0.044), whereas there was no impact
of the number of the prior lines measured as >2 vs ≤2 (HR
1.05, CI 0.75–1.48; P = 0.764) [18]. In the Italian EAP,
everolimus showed just a trend for inferior OS (HR 1.30, CI
0.95–1.76; P = 0.10), whereas the number of prior lines
measured as >1 vs ≤1 showed a statistically significant impact
on OS (HR 1.80, CI 1.15–2.87; P = 0.01) that was confirmed
in multivariate analysis (Table 4). Until recently, everolimus
has been used as standard of care as a second or further line
of therapy. Patients treated with one prior line only did not
receive everolimus; therefore, patients treated with nivolumab
after everolimus could have a prognostic impact because of
more prior lines of therapy received.
Despite the efficacy of nivolumab, a relevant unmet need
remains the development of immuno-inflammatory
biomarkers able to predict long-term clinical benefit in order
to identify which patients with mRCC are likely to have an
advantage from this therapy [19–22]. This is extremely
relevant for the management of nivolumab in patients with
mRCC with an ORR of 25%, and with long-term survival
>4 years in nearly 20% of cases [10,11].
This EAP provides extensive real-world experience with
nivolumab in patients with previously treated mRCC,
including a consistent number of elderly patients and patients
with bone metastases, who were poorly represented in the
pivotal CheckMate 025 study, and patients with brain
metastases and non-clear-cell histotypes, who were not
represented at all [3]. Despite these differences, the safety
profile and efficacy of nivolumab appeared consistent with
that reported in the pivotal trial [3]. Noting the limitations of
this type of study, preliminary data from this EAP appear to
confirm data from the pivotal trial and suggest that
nivolumab is safe and efficacious for the treatment of mRCC
in routine clinical practice.
Acknowledgements
This data collection was financially supported by Bristol-
Myers Squibb. The financial sponsor of the trial had no
Table 4 Association between baseline characteristics and overall survival.
Characteristic Univariate analysis Multivariate analysis
HR (95% CI) P HR (95% CI) P
Age
≥75 vs <75 years 0.62 (0.39–0.98) 0.04 0.55 (0.32–0.96) 0.04
Gender
Male vs female 1.18 (0.82–1.71) 0.36 –
Metastatic site, yes vs no
Bone 1.35 (0.99–1.84) 0.06 –
Liver 1.05 (0.76–1.46) 0.75 –
CNS 1.39 (0.84–2.31) 0.20 –
Number of prior therapies
>1 vs 1 1.80 (1.15–2.87) 0.01 1.87 (1.13–3.09) 0.01
IMDC prognostic group
Intermediate vs favourable 1.97 (1.18–3.31) 0.01 2.06 (1.23–3.46) 0.006
Poor vs favourable 4.20 (2.23–7.93) <0.0001 4.34 (2.30–8.20) <0.001
First-line treatment
Sunitinib vs pazopanib 1.24 (0.84–1.84) 0.28
Prior everolimus
Yes vs no 1.30 (0.95–1.76) 0.10
HR, hazard ratio; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium.
© 2018 The Authors
BJU International © 2018 BJU International 103
Nivolumab EAP: real-world results in RCC
role in the design or conduct of the trial, data collection
or analysis and preparation of the manuscript. The authors
wish to thank all the patients and their families who
participated in the Italian RCC EAP as well as all the
investigators: U. De Giorgi (Meldola), G. Procopio (Milan),
G. Cartenı (Naples), A. Falcone (Pisa), U. Basso (Padova),
E. Cortesi (Rome); F. Roila (Terni), S. Cascinu (Modena),
U. Tirelli (Aviano), S. Buti (Parma), S. Pignata (Naples),
G. Lo Re (Pordenone), A. Berruti (Brescia), S. Bracarda
(Arezzo), F. Cognetti (Roma), L. Giustini (Fermo),
A. Sobrero (Genova), D. Turci (Ravenna), C. N. Sternberg
(Roma), C. Porta (Pavia), F. Cappuzzo (Livorno),
G. Tortora (Verona), D. Tassinari (Rimini), R. Passalacqua
(Cremona), A. Pazzola (Sassari), G. Surico (Lecce),
M. Maio (Siena), G. Benedetti (Macerata), C. Barone
(Roma); V. Adamo (Messina), E. Ricevuto (L’Aquila),
A. De Censi (Genova), M. Spada (Cefalu), G. Tonini
(Roma), C. Pinto (Reggio Emilia), L. Ciuffreda (Torino),
E. M. Ruggeri (Viterbo), C. Bengala (Grosseto), V. Scotti
(Florence), D. Fagnani (Vimercate), A. Bonetti (Legnago),
M. Mitterer (Merano), F. Castiglione (Cuneo), P. Bidoli
(Monza), F. Ferrau (Taormina), L. Crino (Perugia),
A. Frassoldati (Ferrara), P. Marchetti (Roma), E. Mini
(Florence), A. Scoppola (Roma), C. Verusio (Saronno),
A. Favaretto (Treviso), F. Di Costanzo (Florence), G. Fasola
(Udine), M. Merlano (Cuneo), F. Artioli (Carpi), A. Di Leo
(Prato), S. Romito (Foggia), A. Maestri (Imola), C.
Giannitto Giorgio (Caltagirone), M. T. Ionta (Cagliari),
F. Verderame (Palermo), G. Zampa (Roma), G. Numico
(Alessandria), M. Minelli (Roma), P. Tagliaferri (Catanzaro),
P. Foa (Milan), G. Palmiotti (Bari), S. De Placido (Naples),
R. Mattioli (Fano), F. Iuliano (Rossano), E. Defraia
(Cagliari), S. Siena (Milano), M. Clerico (Biella),
L. Salvagno (Vittorio Veneto), G. L. Ceresoli (Bergamo),
A. Bernardo (Pavia), M. Di Lieto (Pistoia), M. Moroni
(Milan), M. Maisano (Reggio Calabria), M. Scartozzi
(Cagliari), G. Scagliotti (Orbassano), M. Soraru (Cittadella),
S. Pepe (Salerno), A. Scaltriti (Guastalla), V. Gebbia
(Palermo), E. Testa (Urbino), V. Lorusso (Bari),
R. Bordonaro (Catania), G. De Signoribus (S. Benedetto del
Tronto), N. Tedde (Olbia), A. Santoro (Rozzano),
G. Francini (Siena), G. Aondio (Gravedona).
Conflict of Interest
Ugo De Giorgi plays a consultant/advisory role in Bristol-
Myers Squibb, Ipsen, Pfizer, Novartis, Astellas, Janssen,
Sanofi. Umberto Basso received speaker fees from Bristol-
Myers Squibb, Pfizer, Novartis, Pierre Fabre, Janssen, Astellas,
Sanofi, and has had an advisory role for Sanofi, Novartis,
MSD, Janssen. Roberto Sabbatini plays a consultant/advisory
role in Bristol-Myers Squibb, Ipsen, Pfizer, Novartis, Astellas,
Janssen, Sanofi. Cora N. Sternberg received honoraria from
Bristol-Myers Squibb, Novartis, Pfizer, Ipsen, Eisai.
References
1 Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:
2443–54
2 Farolfi A, Schepisi G, Conteduca V, Burgio SL, Lolli C, De Giorgi U.
Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab
in the treatment of metastatic renal cell carcinoma. Expert Opin Drug
Metab Toxicol 2016; 12: 1089–96
3 Motzer RJ, Escudier B, McDermott DF et al. Nivolumab versus
everolimus in advanced renal-cell carcinoma. N Engl J Med 2015; 373:
1803–13
4 Administration USFD. FDA Expands Use of Immunotherapeutic to
Kidney Cancer (2015). Available at: https://blog.aacr.org/fda-approval-
nivolumab-kidney-cancer/. Accessed July 2018
5 Agency EM. New treatment for advanced form of kidney cancer (2016).
Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Press_
release/2016/02/WC500202416.pdf. Accessed July 2018
6 Vickers MM, Al-Harbi H, Choueiri TK et al. Prognostic factors of
survival for patients with metastatic renal cell carcinoma with brain
metastases treated with targeted therapy: results from the international
metastatic renal cell carcinoma database consortium. Clin Genitourin
Cancer 2013; 11: 311–5
7 Gore ME, Szczylik C, Porta C et al. Safety and efficacy of sunitinib for
metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol
2009; 10: 757–63
8 Sankin A, Hakimi AA, Hsieh JJ, Molina AM. Metastatic non-clear cell
renal cell carcinoma: an evidence based review of current treatment
strategies. Front Oncol 2015; 5: 67
9 de Velasco G, McKay RR, Lin X, Moreira RB, Simantov R, Choueiri
TK. Comprehensive analysis of survival outcomes in non-clear cell renal
cell carcinoma patients treated in clinical trials. Clin Genitourin Cancer
2017; 15: 652–60
10 Ko JJ, Xie W, Kroeger N et al. The International Metastatic Renal Cell
Carcinoma Database Consortium model as a prognostic tool in patients with
metastatic renal cell carcinoma previously treated with first-line targeted
therapy: a population-based study. Lancet Oncol 2015; 16: 293–300
11 Motzer RJ, Rini BI, McDermott DF et al. Nivolumab for metastatic renal
cell carcinoma: results of a randomized phase II trial. J Clin Oncol 2015;
33: 1430–7
12 McDermott DF, Drake CG, Sznol M et al. Survival, durable response,
and long-term safety in patients with previously treated advanced renal
cell carcinoma receiving nivolumab. J Clin Oncol 2015; 33: 2013–20
13 Joseph RW, Chatta G, Vaishampayan U. Nivolumab treatment for
advanced renal cell carcinoma: considerations for clinical practice. Urol
Oncol 2017; 35: 142–8
14 Dudnik E, Yust-Katz S, Nechushtan H et al. Intracranial response to
nivolumab in NSCLC patients with untreated or progressing CNS
metastases. Lung Cancer 2016; 98: 114–7
15 Kroeger N, Xie W, Lee JL et al. Metastatic non-clear cell renal cell
carcinoma treated with targeted therapy agents: characterization of
survival outcome and application of the International mRCC database
consortium criteria. Cancer 2013; 119: 2999–3006
16 Koshkin VS, Barata PC, Zhang T et al. Clinical activity of nivolumab in
patients with non-clear cell renal cell carcinoma. J Immunother Cancer
2018; 6: 9
17 Escudier B, Sharma P, McDermott DF et al. CheckMate 025 randomized
phase 3 study: outcomes by key baseline factors and prior therapy for
nivolumab versus everolimus in advanced renal cell carcinoma. Eur Urol
2017; 72: 962–71
18 Albiges L, Negrier S, Dalban C et al. Safety and efficacy of nivolumab in
metastatic renal cell carcinoma (mRCC): Results from the NIVOREN
GETUG-AFU 26 study. J Clin Oncol 2018; 36: 577 (suppl 6S; abstr 577)
104
© 2018 The Authors
BJU International © 2018 BJU International
De Giorgi et al.
19 Pal SK, Sonpavde G, Agarwal N et al. Evolution of circulating tumor
DNA profile from first-line to subsequent therapy in metastatic renal cell
carcinoma. Eur Urol 2017; 72: 557–64
20 Lolli C, Basso U, Derosa L et al. Systemic immune-inflammation index
predicts the clinical outcome in patients with metastatic renal cell cancer
treated with sunitinib. Oncotarget 2016; 7: 54564–71
21 Zhu J, Armstrong AJ, Friedlander TW et al. Biomarkers of
immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor
mutational burden, and beyond. J Immunother Cancer 2018; 6: 4
22 Miao D, Margolis CA, Gao W et al. Genomic correlates of response to
immune checkpoint therapies in clear cell renal cell carcinoma. Science
2018; 359: 801–6
Correspondence: Ugo De Giorgi, MD, PhD, Department of
Medical Oncology, Istituto Scientifico Romagnolo per lo
Studio e la Cura dei Tumori (IRST) IRCCS, Via Maroncelli
40, I-47014 Meldola, Italy.
e-mail: ugo.degiorgi@irst.emr.it
Abbreviations: AE, adverse event; EAP, Nivolumab RCC
Early Access Programme; IMDC, International Metastatic
Renal Cell Carcinoma Database Consortium; mRCC,
metastatic RCC; ORR, objective response rate; OS, overall
survival; PD-1, programmed death-1; PFS, progression-free
survival; VEGF, vascular endothelial growth factor.
Supporting Information
Additional supporting information may be found online in
the Supporting Information section at the end of the article:
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patients treated with first-line sunitinib vs pazopanib before
nivolumab in every line of treatment (A) and treated with
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line treatment (B).
© 2018 The Authors
BJU International © 2018 BJU International 105
Nivolumab EAP: real-world results in RCC
